Chipscreen Biosesciences

A Pioneer in Drug Innovation & Development in China

Founded in March 2001 by a group of senior scientists returned from the United States, Chipscreen Biosesciences focuses on developing innovative drugs with new mechanisms of action (MOA) for the treatment of human diseases in five major therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders and antivirals, so as to provide patients with affordable, efficacious drugs to meet their clinical needs.

Chipscreen Biosesciences was the first biotech firm approved for listing on the Shanghai Stock Exchange Science and Technology Innovation Board Market (Stock code: 688321.SH).

Group Overview

Video Library

Senior Management Team

Chipscreen History

Our pioneering journey to bring China-innovated pharmaceuticals to the world began in Shenzhen in 2001.

Fast forward to 2023, we are now a globalized modern biotech firm with integrated research,
production and sales capacity.

More+

21 in Canada

33 in the United States

12 in Mexico

19 in Brazil

7 in South Africa

4 in Egypt

7 in Ukraine

26 in Europe

22 in Russia

226 in China

14 in India

21 in South Korea

23 in Japan

18 in Indonesia

3 in the Philippines

3 in Singapore

3 in the Malaysia

1 in the Vietnam

1 in the Thailand

21 in Australia

54 PCT applications

Intellectual Property

Intellectual Property Chipscreen Biosesciences has a global intellectual property strategy, with patent portfolioses in several countries and regions, including the United States, Europe, Japan, South Korea, India, Australia, Russia, Brazil, Canada, Mexico, Indonesia, Egypt, Ukraine, and South Africa etc.

Till now, Chipscreen has filed over 600 invention patents worldwide, with more than 160 of these granted. The chemical invention patent for our innovative anti-cancer drug Chidamide won a gold award in the 19th China Patent Awards.

Honors

More+

Social Responsibility

We take active steps to fulfill our responsibilities to society, and we take corporate social responsibility to the next level. To ensure the interests of the patients and the public, we have put in place organizational systems and management procedures covering everything from development strategies to day-to-day operations, and appointed professional personnel to control risk across the entire drug lifecycle and supply chain.

We actively undertake public service campaigns as a way of giving back to society.

More+

Our Partners

Research Partners

Business Partners

Founder、 Chairman、 President

Dr. Lu returned to China in September 2000 to take up a position as a senior visiting scholar at the State Key Laboratory of Membrane Biology at Tsinghua University. After founding Chipscreen Biosesciences in 2001, he has successively served as the Chief Scientific Officer, President, Deputy Chairman, and Chairman of Chipscreen Biosesciences.

Dr. Lu graduated with a BSc in biochemistry from Sichuan University in 1983 and PhD in molecular biology from Peking Union Medical College, Chinese Academy of Medical Sciences in 1988. He pursued postdoctoral training at the University of California, San Diego (UCSD) in 1989 and co-founded Maxia Pharmaceuticals and Galderma Research Inc. in San Diego in 1994, serving as Director of Research at Galderma R&D. With more than 30 years of global experience in drug research, development and management, Dr. Lu is highly accomplished in the fields of molecular medicine, oncology, neuroendocrinology, immunity, metabolism and skin diseases. He has published more than 100 articles in top international journals such as Science, Nature, and Lancet, and is named as the first inventor on over 100 invention patents in the field of drug discovery.

Vice President

Head of Product Development and Production

Since 2001, Dr. Li has served as the Group’s Chief Scientist and Director of the Medicinal Chemistry Department before becoming Vice President of Product Development and Production. He was previously Deputy General Manager of Xi’an Kaimi Co., Ltd., and a senior engineer at Xi’an Modern Chemistry Research Institute. Dr. Li graduated from East China University of Science and Technology with a doctorate in applied chemistry.

Board Director and Vice President

Head of Finance

Mr. Li’s roles in the Group have included Finance Department Manager, Board Director, Vice President, and the Chief Financial Officer of the Company. Before joining Chipscreen in 2001 he was an accountant in the Financial Department of Hainan International Investment Co., Ltd., manager in the Financial Department of Hai Guo Tou Industry Share Co., Ltd., and director and Chief Financial Officer of Guangzhou Ruijun Industrial Co., Ltd. Mr. Li graduated from Jinan University with a major in international accounting.

Board Director、 Vice President、 Secretary of the Board

Head of Legal and Intellectual Property Department

Ms. Hai has served successively as an R&D Department assistant, Director of the Legal and Public Affairs Department, and Assistant President of Chipscreen since joining in 2001. She was previously an assistant in the Human Resources Department of Shenzhen Huaji Yuehai Technology Co., Ltd. Ms. Hai graduated from Jilin University, majoring in Economic Law.

Vice President、 Chief Scientific Officer

Head of the Early Research & Development Center

Dr. Pan received his Ph.D. in Biochemistry and Molecular Biology from China Union Medical University (now Peking Union Medical College), before undertaking postdoctoral research at Wayne State University School of Medicine in 2000. Prior to joining Chipscreen Biosesciences in 2002, he was an assistant research fellow at Fuwai Hospital, Chinese Academy of Medical Sciences. Dr. Pan’s roles in Chipscreen have included researcher in the Department of Biological Research, Director of the Drug Discovery Department, Chief Scientific Officer, Head of the Early Research & Development Center, and Vice President.

Vice President

Head of Oncology Division

Mr. She graduated from China Central Radio and Television University. Formerly Manager of Sales at Nanjing Zhenzhong Biology Engineering Co., Ltd. (now Nanjing Luye Pharmaceutical Co., Ltd.), he has 15 years of experience as regional/national Sales Manager of Bayer HealthCare China (incorporating the merged Schering-Plough). In 2013, Mr. She joined Chipscreen Biosesciences and established the oncology division.

Vice President

Head of Metabolic Diseases Division

Mr. Zhang graduated from Heze Medical College. With more than 20 years of experience in vaccines and prescription drug sales, his roles have included Regional Manager at GlaxoSmithKline, Regional Manager at Pfizer, National Marketing Manager at Eli Lilly, and National Sales & Marketing Director at Actis Capital LLP. Mr. Zhang joined Chipscreen Biosesciences in 2020, establishing the Metabolic Diseases Division.

Chipscreen Biosesciences

A Pioneer in Drug Innovation & Development in China

Senior Management Team

Dr. Lu Xianping

Dr. Li Zhibin

Li Jianxun

Hai Ou

Dr. Pan Desi

She Liangji

Zhang Libin

Chipscreen History

Intellectual Property

Honors

Social Responsibility

Our Partners

Research Partners

Business Partners

Dr. Lu Xianping

Founder、 Chairman、 President

Dr. Li Zhibin

Vice President

Head of Product Development and Production

Li Jianxun

Board Director and Vice President

Head of Finance

Hai Ou

Board Director、 Vice President、 Secretary of the Board

Head of Legal and Intellectual Property Department

Dr. Pan Desi

Vice President、 Chief Scientific Officer

Head of the Early Research & Development Center

She Liangji

Vice President

Head of Oncology Division

Zhang Libin

Vice President

Head of Metabolic Diseases Division